Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pemphigoid, Bullous | 6 | 2022 | 114 | 3.330 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 9 | 2022 | 209 | 3.020 |
Why?
|
Skin Neoplasms | 32 | 2024 | 5799 | 2.910 |
Why?
|
Drug Eruptions | 11 | 2024 | 335 | 2.550 |
Why?
|
Exanthema | 5 | 2024 | 504 | 2.430 |
Why?
|
Skin | 23 | 2024 | 4466 | 1.570 |
Why?
|
Scleroderma, Localized | 2 | 2023 | 87 | 1.520 |
Why?
|
Lupus Erythematosus, Cutaneous | 3 | 2020 | 73 | 1.380 |
Why?
|
Paget Disease, Extramammary | 2 | 2021 | 51 | 1.350 |
Why?
|
Histiocytosis, Langerhans-Cell | 2 | 2021 | 169 | 1.290 |
Why?
|
Lymphoproliferative Disorders | 2 | 2022 | 533 | 1.250 |
Why?
|
Mycosis Fungoides | 6 | 2023 | 168 | 1.250 |
Why?
|
Melanoma | 13 | 2024 | 5697 | 1.210 |
Why?
|
Skin Diseases | 7 | 2023 | 1089 | 1.210 |
Why?
|
Lymphomatoid Papulosis | 2 | 2017 | 16 | 1.080 |
Why?
|
Neoplasms | 26 | 2024 | 22072 | 1.030 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 2 | 2017 | 167 | 0.930 |
Why?
|
Oncolytic Virotherapy | 4 | 2023 | 515 | 0.900 |
Why?
|
Pentoxifylline | 1 | 2023 | 53 | 0.890 |
Why?
|
Stomatitis, Aphthous | 1 | 2023 | 52 | 0.860 |
Why?
|
Behcet Syndrome | 1 | 2023 | 86 | 0.840 |
Why?
|
Acitretin | 1 | 2022 | 16 | 0.830 |
Why?
|
Sezary Syndrome | 2 | 2019 | 78 | 0.800 |
Why?
|
Mechlorethamine | 1 | 2020 | 129 | 0.730 |
Why?
|
Genital Neoplasms, Male | 1 | 2021 | 68 | 0.730 |
Why?
|
Dermatomyositis | 2 | 2020 | 256 | 0.720 |
Why?
|
Sterilization | 1 | 2021 | 130 | 0.700 |
Why?
|
Myeloproliferative Disorders | 4 | 2020 | 609 | 0.700 |
Why?
|
Alkylating Agents | 1 | 2020 | 133 | 0.690 |
Why?
|
Edema | 2 | 2023 | 769 | 0.680 |
Why?
|
Fasciitis | 1 | 2020 | 67 | 0.680 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2021 | 211 | 0.670 |
Why?
|
Calciphylaxis | 1 | 2021 | 130 | 0.640 |
Why?
|
Protein Kinase Inhibitors | 6 | 2024 | 5643 | 0.640 |
Why?
|
Quinoxalines | 1 | 2021 | 297 | 0.630 |
Why?
|
Dermatitis, Exfoliative | 1 | 2018 | 27 | 0.630 |
Why?
|
Pityriasis Rubra Pilaris | 1 | 2018 | 18 | 0.620 |
Why?
|
Brachytherapy | 3 | 2021 | 1238 | 0.610 |
Why?
|
Immunotherapy | 17 | 2024 | 4642 | 0.600 |
Why?
|
Cancer Care Facilities | 1 | 2020 | 424 | 0.580 |
Why?
|
Hydrogen Peroxide | 1 | 2021 | 732 | 0.570 |
Why?
|
Dendritic Cells | 6 | 2024 | 2725 | 0.550 |
Why?
|
Antineoplastic Agents | 14 | 2024 | 13630 | 0.540 |
Why?
|
Alopecia | 2 | 2020 | 414 | 0.540 |
Why?
|
Boron Compounds | 1 | 2018 | 180 | 0.540 |
Why?
|
Eosinophilia | 1 | 2020 | 559 | 0.520 |
Why?
|
Acneiform Eruptions | 1 | 2014 | 4 | 0.500 |
Why?
|
Humans | 119 | 2024 | 760621 | 0.490 |
Why?
|
Glycine | 1 | 2018 | 662 | 0.470 |
Why?
|
Facial Dermatoses | 1 | 2015 | 85 | 0.470 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2015 | 321 | 0.470 |
Why?
|
Pyrazoles | 2 | 2024 | 1999 | 0.460 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2023 | 2418 | 0.460 |
Why?
|
Facial Neoplasms | 1 | 2015 | 125 | 0.460 |
Why?
|
Morpholines | 1 | 2017 | 583 | 0.450 |
Why?
|
Vasculitis | 1 | 2018 | 523 | 0.440 |
Why?
|
Psoriasis | 1 | 2022 | 940 | 0.440 |
Why?
|
Pyridazines | 1 | 2015 | 200 | 0.440 |
Why?
|
Vitiligo | 3 | 2024 | 98 | 0.440 |
Why?
|
Pruritus | 1 | 2017 | 377 | 0.440 |
Why?
|
Carcinoid Tumor | 1 | 2015 | 228 | 0.440 |
Why?
|
Granuloma | 1 | 2015 | 327 | 0.420 |
Why?
|
Retrospective Studies | 31 | 2024 | 80372 | 0.410 |
Why?
|
Carcinoma, Squamous Cell | 6 | 2023 | 4024 | 0.380 |
Why?
|
Respiratory Protective Devices | 2 | 2021 | 47 | 0.370 |
Why?
|
Guideline Adherence | 1 | 2020 | 2283 | 0.350 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 4902 | 0.340 |
Why?
|
Aged | 35 | 2024 | 169152 | 0.340 |
Why?
|
Biopsy | 6 | 2022 | 6771 | 0.330 |
Why?
|
Immunocompromised Host | 3 | 2011 | 857 | 0.330 |
Why?
|
Imidazoles | 1 | 2015 | 1180 | 0.330 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1056 | 0.320 |
Why?
|
Paraneoplastic Syndromes | 2 | 2024 | 155 | 0.320 |
Why?
|
Sebaceous Gland Diseases | 1 | 2007 | 5 | 0.310 |
Why?
|
Lung Neoplasms | 5 | 2024 | 13262 | 0.300 |
Why?
|
Dermatitis, Irritant | 2 | 2020 | 18 | 0.290 |
Why?
|
Administration, Cutaneous | 4 | 2023 | 713 | 0.290 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2015 | 951 | 0.290 |
Why?
|
Polyendocrinopathies, Autoimmune | 1 | 2007 | 55 | 0.280 |
Why?
|
Breast Neoplasms | 7 | 2024 | 21025 | 0.280 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1096 | 0.280 |
Why?
|
Radioimmunotherapy | 2 | 2024 | 91 | 0.280 |
Why?
|
Adrenal Cortex Hormones | 2 | 2020 | 1869 | 0.280 |
Why?
|
Thigh | 2 | 2021 | 240 | 0.280 |
Why?
|
Herpes Simplex | 1 | 2010 | 478 | 0.270 |
Why?
|
Head and Neck Neoplasms | 1 | 2020 | 2882 | 0.260 |
Why?
|
Administration, Topical | 2 | 2020 | 697 | 0.260 |
Why?
|
Female | 42 | 2024 | 391270 | 0.260 |
Why?
|
Hamartoma | 1 | 2007 | 235 | 0.250 |
Why?
|
Male | 45 | 2024 | 359744 | 0.250 |
Why?
|
Nevus, Pigmented | 1 | 2007 | 221 | 0.250 |
Why?
|
Middle Aged | 32 | 2024 | 220352 | 0.240 |
Why?
|
Hematologic Neoplasms | 4 | 2024 | 1895 | 0.220 |
Why?
|
Stevens-Johnson Syndrome | 2 | 2022 | 244 | 0.200 |
Why?
|
Erythema Multiforme | 1 | 2022 | 31 | 0.200 |
Why?
|
Dioxygenases | 1 | 2024 | 335 | 0.200 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2023 | 124 | 0.200 |
Why?
|
Diagnosis, Differential | 5 | 2020 | 12965 | 0.200 |
Why?
|
Aged, 80 and over | 15 | 2024 | 58995 | 0.200 |
Why?
|
Enterocolitis | 1 | 2022 | 106 | 0.190 |
Why?
|
Connective Tissue Diseases | 1 | 2024 | 286 | 0.190 |
Why?
|
Dermatology | 2 | 2022 | 914 | 0.190 |
Why?
|
Biological Therapy | 1 | 2022 | 139 | 0.190 |
Why?
|
Molecular Targeted Therapy | 4 | 2020 | 2803 | 0.180 |
Why?
|
Equipment Reuse | 1 | 2021 | 45 | 0.180 |
Why?
|
Lymphoma, T-Cell | 1 | 2023 | 305 | 0.180 |
Why?
|
Gastritis | 1 | 2022 | 198 | 0.180 |
Why?
|
Decontamination | 1 | 2021 | 72 | 0.180 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6853 | 0.180 |
Why?
|
Myasthenia Gravis | 1 | 2023 | 213 | 0.180 |
Why?
|
Dermatitis | 1 | 2022 | 200 | 0.180 |
Why?
|
Sulfonamides | 3 | 2016 | 1977 | 0.180 |
Why?
|
Dermatitis, Occupational | 1 | 2020 | 26 | 0.180 |
Why?
|
Histamine Antagonists | 1 | 2020 | 90 | 0.180 |
Why?
|
Myositis | 1 | 2023 | 269 | 0.180 |
Why?
|
Equipment and Supplies, Hospital | 1 | 2020 | 59 | 0.180 |
Why?
|
Practice Guidelines as Topic | 4 | 2021 | 7475 | 0.170 |
Why?
|
Case-Control Studies | 4 | 2022 | 22053 | 0.170 |
Why?
|
Combined Modality Therapy | 3 | 2023 | 8552 | 0.170 |
Why?
|
Antibodies, Monoclonal | 6 | 2024 | 9185 | 0.170 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2022 | 4353 | 0.170 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2023 | 2053 | 0.170 |
Why?
|
Eczema | 1 | 2022 | 245 | 0.170 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2020 | 5649 | 0.170 |
Why?
|
Fluorescent Antibody Technique | 1 | 2024 | 2471 | 0.170 |
Why?
|
Cytotoxins | 1 | 2020 | 153 | 0.170 |
Why?
|
Consensus | 3 | 2024 | 3113 | 0.170 |
Why?
|
Antibodies, Antinuclear | 1 | 2020 | 344 | 0.160 |
Why?
|
Purpura Fulminans | 1 | 2018 | 21 | 0.160 |
Why?
|
Nitriles | 1 | 2024 | 956 | 0.160 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2023 | 380 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-bcl-6 | 1 | 2019 | 191 | 0.160 |
Why?
|
Disease Management | 2 | 2020 | 2514 | 0.160 |
Why?
|
Quality of Life | 5 | 2024 | 13308 | 0.160 |
Why?
|
Penile Neoplasms | 1 | 2020 | 162 | 0.160 |
Why?
|
Bandages | 1 | 2020 | 270 | 0.160 |
Why?
|
Protein C | 1 | 2018 | 133 | 0.160 |
Why?
|
Upper Extremity | 1 | 2023 | 661 | 0.150 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2018 | 71 | 0.150 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2020 | 3616 | 0.150 |
Why?
|
Thrombomodulin | 1 | 2018 | 105 | 0.150 |
Why?
|
Ultraviolet Rays | 1 | 2023 | 1078 | 0.150 |
Why?
|
Chromosomes, Human, Pair 3 | 1 | 2019 | 315 | 0.150 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2024 | 800 | 0.140 |
Why?
|
Adult | 21 | 2024 | 219994 | 0.140 |
Why?
|
Scalp | 1 | 2020 | 389 | 0.140 |
Why?
|
Arthritis, Rheumatoid | 2 | 2023 | 3763 | 0.140 |
Why?
|
Stomatitis | 1 | 2020 | 271 | 0.140 |
Why?
|
Mouth | 1 | 2020 | 380 | 0.140 |
Why?
|
Cohort Studies | 10 | 2024 | 41335 | 0.140 |
Why?
|
Prognosis | 8 | 2024 | 29658 | 0.140 |
Why?
|
Oligodendroglioma | 1 | 2018 | 279 | 0.140 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 427 | 0.130 |
Why?
|
Withholding Treatment | 1 | 2020 | 613 | 0.130 |
Why?
|
Pancreatitis | 1 | 2023 | 1100 | 0.130 |
Why?
|
Glucocorticoids | 2 | 2022 | 2145 | 0.130 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2020 | 640 | 0.130 |
Why?
|
Cell Death | 2 | 2023 | 1672 | 0.130 |
Why?
|
Substance P | 1 | 2017 | 333 | 0.130 |
Why?
|
Pityriasis | 1 | 2015 | 11 | 0.130 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2023 | 3602 | 0.130 |
Why?
|
Pilot Projects | 3 | 2024 | 8555 | 0.130 |
Why?
|
Treatment Outcome | 10 | 2022 | 65017 | 0.130 |
Why?
|
Myocarditis | 1 | 2023 | 766 | 0.130 |
Why?
|
Immunologic Factors | 3 | 2023 | 1588 | 0.130 |
Why?
|
Folliculitis | 1 | 2015 | 25 | 0.130 |
Why?
|
Epidermolysis Bullosa Dystrophica | 1 | 2015 | 28 | 0.130 |
Why?
|
Mutation | 7 | 2024 | 29932 | 0.120 |
Why?
|
Urogenital Neoplasms | 1 | 2016 | 135 | 0.120 |
Why?
|
Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
Ichthyosis | 1 | 2015 | 59 | 0.120 |
Why?
|
Cholangiocarcinoma | 1 | 2021 | 550 | 0.120 |
Why?
|
Bile Duct Neoplasms | 1 | 2021 | 602 | 0.120 |
Why?
|
Hypothermia, Induced | 1 | 2020 | 758 | 0.120 |
Why?
|
Indoles | 2 | 2014 | 1829 | 0.120 |
Why?
|
Benzoyl Peroxide | 1 | 2014 | 22 | 0.120 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 895 | 0.120 |
Why?
|
Xanthomatosis | 1 | 2014 | 32 | 0.120 |
Why?
|
DNA-Binding Proteins | 2 | 2024 | 9585 | 0.120 |
Why?
|
Clindamycin | 1 | 2014 | 140 | 0.120 |
Why?
|
Colitis | 1 | 2022 | 1229 | 0.110 |
Why?
|
Antirheumatic Agents | 1 | 2023 | 1374 | 0.110 |
Why?
|
Antimalarials | 1 | 2020 | 906 | 0.110 |
Why?
|
Minocycline | 1 | 2014 | 168 | 0.110 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2023 | 2828 | 0.110 |
Why?
|
Taxoids | 1 | 2016 | 669 | 0.110 |
Why?
|
Clone Cells | 3 | 2023 | 1660 | 0.110 |
Why?
|
Hidradenitis Suppurativa | 1 | 2016 | 173 | 0.110 |
Why?
|
Radiotherapy | 1 | 2019 | 1504 | 0.100 |
Why?
|
Urologic Neoplasms | 1 | 2016 | 320 | 0.100 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 936 | 0.100 |
Why?
|
Keratoacanthoma | 1 | 2012 | 33 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1791 | 0.100 |
Why?
|
Proto-Oncogene Proteins | 1 | 2024 | 4490 | 0.100 |
Why?
|
Chlorhexidine | 1 | 2013 | 160 | 0.100 |
Why?
|
Pyrimidines | 1 | 2024 | 3016 | 0.100 |
Why?
|
Biological Products | 1 | 2020 | 916 | 0.100 |
Why?
|
T-Lymphocyte Subsets | 1 | 2019 | 1810 | 0.100 |
Why?
|
Acanthamoeba | 1 | 2010 | 12 | 0.090 |
Why?
|
Skin Diseases, Parasitic | 1 | 2010 | 13 | 0.090 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3696 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2016 | 3584 | 0.090 |
Why?
|
Leukemia | 2 | 2016 | 1520 | 0.090 |
Why?
|
Amebiasis | 1 | 2010 | 33 | 0.090 |
Why?
|
Occupational Exposure | 1 | 2021 | 1809 | 0.090 |
Why?
|
Nervous System Diseases | 1 | 2021 | 1647 | 0.090 |
Why?
|
Anti-Infective Agents, Local | 1 | 2013 | 247 | 0.090 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2015 | 685 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 1407 | 0.090 |
Why?
|
Lymphoma | 2 | 2016 | 1898 | 0.090 |
Why?
|
Survival Rate | 3 | 2021 | 12808 | 0.090 |
Why?
|
Astrocytoma | 1 | 2014 | 775 | 0.080 |
Why?
|
Catheter-Related Infections | 1 | 2013 | 273 | 0.080 |
Why?
|
Early Detection of Cancer | 1 | 2024 | 3202 | 0.080 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2015 | 615 | 0.080 |
Why?
|
Phototherapy | 2 | 2023 | 368 | 0.080 |
Why?
|
T-Lymphocytes | 3 | 2022 | 10181 | 0.080 |
Why?
|
Paclitaxel | 1 | 2016 | 1736 | 0.080 |
Why?
|
Pandemics | 4 | 2021 | 8624 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2313 | 0.080 |
Why?
|
Transplantation Conditioning | 1 | 2015 | 1588 | 0.080 |
Why?
|
Immunosuppressive Agents | 4 | 2016 | 4166 | 0.070 |
Why?
|
Eyelashes | 1 | 2007 | 19 | 0.070 |
Why?
|
Keratosis, Seborrheic | 1 | 2007 | 27 | 0.070 |
Why?
|
Massachusetts | 1 | 2020 | 8803 | 0.070 |
Why?
|
Primary Health Care | 1 | 2024 | 4647 | 0.070 |
Why?
|
Eyebrows | 1 | 2007 | 35 | 0.070 |
Why?
|
Lymphocytes | 1 | 2015 | 2611 | 0.070 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 1628 | 0.070 |
Why?
|
Fatal Outcome | 2 | 2010 | 1832 | 0.070 |
Why?
|
Disease-Free Survival | 1 | 2017 | 6828 | 0.070 |
Why?
|
Risk Factors | 4 | 2023 | 74359 | 0.070 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 2 | 2019 | 345 | 0.060 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2011 | 1791 | 0.060 |
Why?
|
Photochemotherapy | 1 | 2012 | 820 | 0.060 |
Why?
|
Nails | 1 | 2007 | 295 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 5251 | 0.060 |
Why?
|
Ligands | 2 | 2022 | 3276 | 0.060 |
Why?
|
Immunologic Memory | 1 | 2012 | 1354 | 0.060 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2012 | 1765 | 0.060 |
Why?
|
Protein Binding | 1 | 2017 | 9335 | 0.060 |
Why?
|
Radiography | 1 | 2015 | 6965 | 0.060 |
Why?
|
Receptor, erbB-2 | 1 | 2014 | 2554 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 11712 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2020 | 4775 | 0.050 |
Why?
|
MutS Homolog 2 Protein | 1 | 2023 | 195 | 0.050 |
Why?
|
Ultrasonography | 1 | 2015 | 5961 | 0.050 |
Why?
|
Sunlight | 1 | 2024 | 337 | 0.050 |
Why?
|
Survival Analysis | 3 | 2020 | 10182 | 0.050 |
Why?
|
United States | 2 | 2021 | 72461 | 0.050 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2023 | 412 | 0.050 |
Why?
|
Adolescent | 4 | 2022 | 87810 | 0.050 |
Why?
|
Computers, Handheld | 1 | 2024 | 210 | 0.050 |
Why?
|
Medicare | 1 | 2020 | 6786 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 9276 | 0.050 |
Why?
|
Cell Lineage | 2 | 2023 | 2533 | 0.050 |
Why?
|
Containment of Biohazards | 1 | 2020 | 37 | 0.050 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2024 | 556 | 0.040 |
Why?
|
Aminopyridines | 1 | 2024 | 564 | 0.040 |
Why?
|
Injections, Intralesional | 1 | 2020 | 278 | 0.040 |
Why?
|
DNA Mismatch Repair | 1 | 2023 | 429 | 0.040 |
Why?
|
Endocrine System | 1 | 2020 | 112 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39261 | 0.040 |
Why?
|
Transcription Factors | 1 | 2019 | 12103 | 0.040 |
Why?
|
Capnocytophaga | 1 | 2018 | 26 | 0.040 |
Why?
|
Ventilators, Mechanical | 1 | 2021 | 287 | 0.040 |
Why?
|
Delphi Technique | 1 | 2022 | 829 | 0.040 |
Why?
|
ras Proteins | 1 | 2024 | 1052 | 0.040 |
Why?
|
Liver Transplantation | 1 | 2010 | 2325 | 0.040 |
Why?
|
Masks | 1 | 2021 | 209 | 0.040 |
Why?
|
Disinfection | 1 | 2021 | 209 | 0.040 |
Why?
|
Cell Line, Tumor | 3 | 2023 | 16939 | 0.040 |
Why?
|
Child | 3 | 2022 | 79806 | 0.040 |
Why?
|
Organ Specificity | 1 | 2023 | 1955 | 0.040 |
Why?
|
Graft vs Host Disease | 1 | 2010 | 3025 | 0.040 |
Why?
|
Disease Progression | 3 | 2022 | 13502 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 10827 | 0.040 |
Why?
|
Transplantation, Homologous | 2 | 2016 | 4810 | 0.040 |
Why?
|
Young Adult | 2 | 2020 | 58741 | 0.030 |
Why?
|
Time-Lapse Imaging | 1 | 2017 | 193 | 0.030 |
Why?
|
Oncolytic Viruses | 1 | 2020 | 343 | 0.030 |
Why?
|
Radiodermatitis | 1 | 2016 | 58 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 861 | 0.030 |
Why?
|
E-Selectin | 1 | 2018 | 576 | 0.030 |
Why?
|
Nail Diseases | 1 | 2016 | 55 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2022 | 1063 | 0.030 |
Why?
|
Endothelium | 1 | 2018 | 764 | 0.030 |
Why?
|
Pigmentation Disorders | 1 | 2016 | 105 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2017 | 329 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 225 | 0.030 |
Why?
|
Diarrhea | 1 | 2022 | 1319 | 0.030 |
Why?
|
Collagen Type VII | 1 | 2015 | 22 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2023 | 2414 | 0.030 |
Why?
|
Herpesvirus 1, Human | 1 | 2020 | 753 | 0.030 |
Why?
|
SEER Program | 1 | 2020 | 1530 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2018 | 1006 | 0.030 |
Why?
|
Myeloablative Agonists | 1 | 2015 | 209 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1841 | 0.030 |
Why?
|
Busulfan | 1 | 2015 | 258 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 353 | 0.030 |
Why?
|
Neoplasm Staging | 3 | 2014 | 11152 | 0.030 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 223 | 0.030 |
Why?
|
Transplantation Immunology | 1 | 2016 | 532 | 0.030 |
Why?
|
Face | 1 | 2020 | 1017 | 0.030 |
Why?
|
Vidarabine | 1 | 2015 | 336 | 0.030 |
Why?
|
Neurotoxicity Syndromes | 1 | 2017 | 299 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 713 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 368 | 0.030 |
Why?
|
Heterozygote | 1 | 2020 | 2798 | 0.030 |
Why?
|
Triage | 1 | 2020 | 987 | 0.030 |
Why?
|
Radiotherapy Dosage | 1 | 2020 | 2897 | 0.030 |
Why?
|
Occlusive Dressings | 1 | 2013 | 52 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2014 | 8986 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8515 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2020 | 1405 | 0.030 |
Why?
|
Valine | 1 | 2014 | 409 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2017 | 1871 | 0.030 |
Why?
|
Acute Disease | 1 | 2023 | 7269 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2014 | 0.030 |
Why?
|
Autoimmune Diseases | 1 | 2024 | 2250 | 0.020 |
Why?
|
Pyridines | 1 | 2024 | 2879 | 0.020 |
Why?
|
Polyomavirus Infections | 1 | 2014 | 194 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2016 | 1837 | 0.020 |
Why?
|
Mice | 4 | 2023 | 81208 | 0.020 |
Why?
|
Survivors | 1 | 2022 | 2375 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2394 | 0.020 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2024 | 2276 | 0.020 |
Why?
|
Aminolevulinic Acid | 1 | 2012 | 142 | 0.020 |
Why?
|
Microfluidic Analytical Techniques | 1 | 2017 | 806 | 0.020 |
Why?
|
Tumor Virus Infections | 1 | 2014 | 438 | 0.020 |
Why?
|
Gene Expression | 1 | 2023 | 7588 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2019 | 2013 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2569 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2017 | 1664 | 0.020 |
Why?
|
Infant | 3 | 2020 | 36060 | 0.020 |
Why?
|
Patient Care Team | 1 | 2021 | 2511 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2017 | 6131 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2023 | 4550 | 0.020 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2014 | 733 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2024 | 14660 | 0.020 |
Why?
|
Glutamic Acid | 1 | 2014 | 1167 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2012 | 586 | 0.020 |
Why?
|
Catheterization, Central Venous | 1 | 2013 | 526 | 0.020 |
Why?
|
Frontal Lobe | 1 | 2014 | 1420 | 0.020 |
Why?
|
Photosensitizing Agents | 1 | 2012 | 618 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2017 | 5870 | 0.020 |
Why?
|
Temporal Lobe | 1 | 2014 | 1688 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5797 | 0.020 |
Why?
|
Hospitals | 1 | 2020 | 3928 | 0.020 |
Why?
|
Animals | 4 | 2023 | 167963 | 0.020 |
Why?
|
Health Personnel | 1 | 2020 | 3310 | 0.020 |
Why?
|
Immune System | 1 | 2012 | 798 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4899 | 0.020 |
Why?
|
Phenotype | 2 | 2016 | 16546 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1855 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10551 | 0.020 |
Why?
|
Societies, Medical | 1 | 2017 | 3905 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2525 | 0.020 |
Why?
|
Fibroblasts | 1 | 2015 | 4090 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2023 | 5325 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12159 | 0.010 |
Why?
|
Incidence | 1 | 2023 | 21392 | 0.010 |
Why?
|
Logistic Models | 1 | 2019 | 13314 | 0.010 |
Why?
|
Glycoproteins | 1 | 2012 | 2208 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2023 | 18137 | 0.010 |
Why?
|
Child, Preschool | 2 | 2020 | 42063 | 0.010 |
Why?
|
Recurrence | 1 | 2016 | 8482 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11071 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3610 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2012 | 1998 | 0.010 |
Why?
|
Internet | 1 | 2016 | 3078 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2015 | 3663 | 0.010 |
Why?
|
Anticoagulants | 1 | 2018 | 4897 | 0.010 |
Why?
|
Organ Transplantation | 1 | 2013 | 1150 | 0.010 |
Why?
|
Cytokines | 1 | 2017 | 7343 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2017 | 5253 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2016 | 3075 | 0.010 |
Why?
|
Risk Assessment | 1 | 2024 | 24123 | 0.010 |
Why?
|
Lung | 1 | 2020 | 9994 | 0.010 |
Why?
|
Antigens, CD | 1 | 2012 | 4000 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2016 | 10446 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2010 | 6498 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2015 | 12766 | 0.010 |
Why?
|
Research Design | 1 | 2016 | 6180 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2016 | 9411 | 0.010 |
Why?
|
Critical Illness | 1 | 2013 | 2709 | 0.010 |
Why?
|
Neutrophils | 1 | 2012 | 3767 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10344 | 0.010 |
Why?
|
Sepsis | 1 | 2013 | 2592 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 17790 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2016 | 15840 | 0.010 |
Why?
|
Graft Rejection | 1 | 2010 | 4426 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 6465 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2014 | 36290 | 0.010 |
Why?
|
Prospective Studies | 1 | 2019 | 54303 | 0.010 |
Why?
|